BlueAllele Corporation Files Lawsuit for Patent Infringement against Intellia Therapeutics, Inc., for the Unauthorized Use of BlueAllele’s Patented Bi-directional Insertion Templates
08 Julio 2024 - 4:11PM
Business Wire
BlueAllele® Corporation, a biotechnology company focused on
advancing transformational gene editing technologies, filed a
patent infringement lawsuit against Intellia Therapeutics in the
United States District Court for the District of Delaware. The
complaint alleges infringement of BlueAllele’s bi-directional
insertion template patents, which cover the company’s
transformational platform used in the development and treatment of
genetic diseases.
The novel design of BlueAllele’s bi-directional insertion
template technology has unlocked the full potential of the cell’s
highly active NHEJ pathway. Use of the patented bi-directional
insertion template technology can increase the efficacy of gene
editing events, improve safety, and allow development of
therapeutics for a wide range of diseases. As alleged in the
complaint, Intellia has utilized BlueAllele’s patented platform
technology to advance internal programs as well as external
collaboration programs.
BlueAllele develops methodologies for single-dose in vivo
treatments to cure the most debilitating and devastating genetic
diseases. BlueAllele has actively protected its inventions
resulting in a substantial patent estate. “BlueAllele’s patents
cover our novel and innovative technology for achieving precise
gene editing,” said Dr. Nicholas J. Baltes, BlueAllele’s chief
scientific officer. “Protecting BlueAllele’s intellectual property
is a critical part of our business.”
BlueAllele has expanded upon its bi-directional insertion
template technology with the design of additional platforms for
treating specific classes of genetic diseases, including
bi-directional templates with RNAi cassettes for autosomal dominant
diseases and functions to remove unwanted gene products while
simultaneously restoring normal protein function. Further,
BlueAllele has developed bi-directional templates with dual
terminators designed to address repeat expansion diseases and
functions to prevent transcription through the expansion.
“BlueAllele has been at the forefront of gene editing
technologies,” said Joseph B. Saluri, BlueAllele’s chief executive
officer. “The purpose of this lawsuit is to protect our patent
rights and to ensure our ability to continue conceiving and
advancing transformational technologies for patients with genetic
diseases.”
BlueAllele Corporation is being represented in the lawsuit by
Fish & Richardson P.C. and Schwartz Law Firm.
About BlueAllele
BlueAllele Corporation is a biotechnology company committed to
advancing transformational gene editing technologies, including its
patented PALIDON®, PALIDON+™, and PALIDON DT™ repair template
platforms. For more information, visit www.blueallele.com.
About BlueAllele’s Patents
The patents asserted in the complaint are U.S. patent
11,091,756, U.S. Patent 11,254,930 and U.S. patent 11,365,407.
The ’756, ’930, and ’407 Patents are exclusively owned by
BlueAllele Corporation and cover the company’s bi-directional
insertion template technology for gene editing.
BlueAllele maintains patents in various jurisdictions around the
world on its bi-directional insertion template technology.
BlueAllele®, PALIDON®, PALIDON+™, and PALIDON DT™ are registered
trademarks of BlueAllele Corporation.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20240708896620/en/
Makayla Smith 515-974-4736 msmith@trilix.com